<DOC>
	<DOCNO>NCT02317484</DOCNO>
	<brief_summary>The purpose study evaluate clinical efficacy safety Sodium Glucose Co-transporter 2 ( SGLT2 ) inhibitor , ipragliflozin , dose 50mg 100mg , Type II Diabetes usual care . It also investigate analyze exploratory influential factor ipragliflozin treatment clinical efficacy safety .</brief_summary>
	<brief_title>Investigation Clinical Efficacy Safety Ipragliflozin 50mg 100mg Type II Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Diabetes Mellitus , Type 2 patient poorlycontrolled diet exercise therapy additional treatment various diabetic drug 2 . Patients change within + 0.5 % HbA1c 3 . Patients variation 6.5 % = &lt; HbA1C = &lt; 10 % 4 . Patients write informed consent 5 . Patients whose BMI = &gt; 20kg/m2 1 . Patients Diabetes Mellitus , Type 1 , type diabetes pregnancy diabetes 2 . Patients history severe ketoacidosis , diabetic coma profound coma last 6 month 3 . Patients severe infection , perioperative period severe trauma 4 . Patients moderate renal insufficiency ( serum creatinine level : male great equal 1.5mg/dL„ÄÅfemale great equal to1.3mg/dL ) 5 . Patients severe hepatic impairment ( judged attend doctor ) 6 . Patients history requirement hospitalization severe cardiovascular event last 6 month consent 7 . Patients pregnancy , breastfeeding , childbearing potential plan pregnancy 8 . Patients neuropathic bladder dysuria 9 . Patients treatment diuretic 10 . Patients SGLT2 treatment kickoff point study 11 . Patients history hypersensitivity SGLT2 inhibitor 12 . Patients judge ineligible principal investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>